Share Email Print
cover

Proceedings Paper

In situ photoimmunotherapy for melanoma: preliminary clinical results
Author(s): Mark F. Naylor; Robert E. Nordquist; T. Kent Teauge; Lisa A. Perry; Wei R. Chen
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Although melanoma accounts for only 4% of skin cancer cases, it causes 79% of all skin cancer deaths. Patients with metastatic melanoma have a poor prognosis, and long term survival is only about 5% [1, 2]. Conventional therapies such as surgery and radiation therapy usually do not cure stage III or stage IV melanoma, while traditional chemotherapy is primarily palliative. Over the last decade we have been developing new methods for treating solid tumors like melanoma, first in animal models and now in humans. We present here preliminary results from a new technique that utilizes a combination of laser stimulation and drug therapy to stimulate brisk immunological responses in cases of advanced melanoma with cutaneous metastases. A high-power, near-infrared diode laser (805 nm) is used to kill tumors in situ and a topical toll-like receptor agonist (imiquimod cream, 5%) is used to intensify the resulting immunological response. This is essentially an in situ, tumor vaccine approach to treating solid tumors.

Paper Details

Date Published: 24 February 2006
PDF: 7 pages
Proc. SPIE 6087, Biophotonics and Immune Responses, 608709 (24 February 2006); doi: 10.1117/12.644882
Show Author Affiliations
Mark F. Naylor, Oklahoma Medical Research Foundation (United States)
Robert E. Nordquist, Wound Healing of Oklahoma (United States)
T. Kent Teauge, Univ. of Oklahoma College of Medicine (United States)
Univ. of Oklahoma (United States)
Oklahoma State Univ. Ctr. for Health Sciences (United States)
Lisa A. Perry, Oklahoma Medical Research Foundation (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)


Published in SPIE Proceedings Vol. 6087:
Biophotonics and Immune Responses
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top